2026 ICD-10-CM Diagnosis Code C79.00Secondary malignant neoplasm of unspecified kidney and renal pelvis

ICD-10-CM CodesC00–D49C76-C80C79

ICD-10-CM C79.00
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

C79.00 is a billable ICD-10-CM diagnosis code for secondary malignant neoplasm of unspecified kidney and renal pelvis. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 656 through 658, 686 through 688. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Secondary malignancies.

Code Identity

ICD-10-CM Code
C79.00
Billable Status
Yes — Valid for Submission
Code Describes
Secondary malignant neoplasm of unspecified kidney and renal pelvis
Short Description
Secondary malignant neoplasm of unsp kidney and renal pelvis
Parent Code
Secondary malignant neoplasm of kidney and renal pelvis

Code Classification

ChapterC00–D49Neoplasms
SectionC76-C80Malignant neoplasms of ill-defined, other secondary and unspecified sites
CategoryC79Secondary malignant neoplasm of other and unspecified sites
This CodeC79.00Secondary malignant neoplasm of unspecified kidney and renal pelvis

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Carcinoma of renal pelvis
  • Chromophobe renal cell carcinoma
  • Cystadenocarcinoma of kidney
  • Leukemic infiltrate of kidney
  • Lymphoma of kidney
  • Lymphomatous infiltrate of kidney
  • Malignant melanoma metastatic to kidney
  • Metastatic chromophobe renal cell carcinoma
  • Metastatic cystadenocarcinoma to kidney
  • Metastatic malignant neoplasm to kidney
  • Metastatic malignant neoplasm to renal pelvis
  • Metastatic MiT family translocation renal cell carcinoma
  • Metastatic papillary cystadenocarcinoma to kidney
  • Metastatic papillary renal cell carcinoma
  • Metastatic renal cell carcinoma
  • Metastatic small cell neuroendocrine carcinoma
  • Metastatic transitional cell carcinoma to kidney
  • Metastatic transitional cell carcinoma to renal pelvis
  • Metastatic transitional cell carcinoma to upper urinary tract
  • MiT family translocation renal cell carcinoma
  • Papillary cystadenocarcinoma of kidney
  • Papillary renal cell carcinoma
  • Secondary adenocarcinoma of kidney
  • Secondary undifferentiated large cell malignant neoplasm of kidney
  • Small cell carcinoma metastatic to kidney

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO070
Secondary malignancies
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Metastatic Chromophobe Renal Cell Carcinoma

    chromophobe renal cell carcinoma that has spread from the original site of growth to another anatomic site.
  • Metastatic Papillary Renal Cell Carcinoma

    a papillary renal cell carcinoma that has spread from the original site of growth to another anatomic site.
  • Metastatic Chromophobe Renal Cell Carcinoma

    a chromophobe renal cell carcinoma that has spread from the original site of growth to another anatomic site.

Table of NeoplasmsClinical

Anatomical sites in the Table of Neoplasms that reference this code family.

SiteMalig.
Primary
Malig.
Secondary
Ca
in situ
BenignUncertainUnspec.
calyx, renalC65.C79.0D09.19D30.1D41.1D49.51
junction pelviuretericC65.C79.0D09.19D30.1D41.1D49.59
kidney (parenchymal)C64.C79.0D09.19D30.0D41.0D49.51
kidney (parenchymal) calyxC65.C79.0D09.19D30.1D41.1D49.51
kidney (parenchymal) hilusC65.C79.0D09.19D30.1D41.1D49.51
kidney (parenchymal) pelvisC65.C79.0D09.19D30.1D41.1D49.51
parenchyma, kidneyC64.C79.0D09.19D30.0D41.0D49.51
pelvis, pelvic renalC65.C79.0D09.19D30.1D41.1D49.51
renalC64.C79.0D09.19D30.0D41.0D49.51
renal calyxC65.C79.0D09.19D30.1D41.1D49.51
renal hilusC65.C79.0D09.19D30.1D41.1D49.51
renal parenchymaC64.C79.0D09.19D30.0D41.0D49.51
renal pelvisC65.C79.0D09.19D30.1D41.1D49.51

Patient EducationClinical

Kidney Cancer

You have two kidneys. They are fist-sized organs on either side of your backbone above your waist. The tubes inside filter and clean your blood, taking out waste products and making urine. Kidney cancer forms in the lining of tiny tubes inside your kidneys.

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert C79.00 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
198.0 Second malig neo kidney
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About C79.00Overview

Is C79.00 (Secondary malignant neoplasm of kidney and renal pelvis) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report secondary malignant neoplasm of unspecified kidney and renal pelvis on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does C79.00 group to?

When secondary malignant neoplasm of unspecified kidney and renal pelvis is the principal diagnosis on an inpatient stay, it groups to MS-DRG 656, 657, 658, 686, 687, 688, with relative weights from 0.7903 to 3.1838 depending on complications. Higher weights mean higher Medicare reimbursement.

What is the ICD-9 equivalent of C79.00?

Under the General Equivalence Mappings, secondary malignant neoplasm of unspecified kidney and renal pelvis converts to ICD-9-CM 198.0 (second malig neo kidney). The mapping is approximate, so confirm the match fits the documentation.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.